December 2017

New Product - Intuniv

Intuniv (guanfacine (hydrochloride)) is a selective α_2A-adrenergic receptor agonist. The mode of action of guanfacine in attention deficit hyperactivity disorder (ADHD) is not fully established. Preclinical research suggests guanfacine modulates signalling in the prefrontal cortex and basal ganglia through direct modification of synaptic norepinephrine transmission at the α₂-adrenergic receptors. Intuniv is indicated for the treatment of ADHD in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a suboptimal response to psychostimulants). Intuniv must be used as part of a comprehensive ADHD management program, typically including psychological, educational and social measures. Intuniv modified release tablets (guanfacine 1 mg, 2 mg, 3 mg or 4 mg) are available in packs of 28.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au